What Content Should Be Included In A Dual Submission?

By clicking “Accept”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.AcceptDenyPreferencesPrivacy Privacy PreferencesEssential cookiesRequiredMarketing cookiesEssentialPersonalization cookiesEssentialAnalytics cookiesEssentialAllow all cookiesReject all cookiesSave preferencesServicesFeatured ResourceBlogHow AI (Artificial Intelligence) Dentistry is Transforming the Dental Device IndustryRegulatoryClinicalQualitySpeak to an ExpertIndustriesFeatured ResourceTools & TemplatesUS FDA vs Health CanadaMedTechBiotechSpeak to an ExpertTherapeuticsFeatured ResourceCase StudiesDedicated Regulatory Team Takes Charge Of An FDA 510(k) ReviewCardiovascularOncologyPediatricsNeuromodulationOrthopedic & SpineIn-Vitro Diagnostics (IVD)General SurgerySpeak to an ExpertResourcesFeatured ResourceFrequently Asked Questions21 CFR 50.27(a) requires that a copy of the consent document be given to the person signing the form. Does this copy have to be a photocopy of the form with the subject's signature affixed?Resource HubInsightsTools & TemplatesIndustry FAQsGlossary of TermsVideo HubBreakthrough Device DesignationSearch Our Resource HubCompanyFeatured ResourceCase StudyDedicated Regulatory Team Takes Charge Of An FDA 510(k) ReviewAbout ProximaMeet our ExpertsJoin our TeamCompany News & PressSpeak to an ExpertContactContactBack to FAQsFrequently Asked QuestionsWhat content should be included in a Dual Submission? MedTechNo items found.Compliance & Regulatory: MedTechGuidelines & StandardsClinical Trials

A Dual Submission should contain the same information as a complete 510(k) and CLIA Waiver by Application. Content related to the comparison and reproducibility studies may overlap and, therefore, a single set of comparison and reproducibility studies may be used to support both 510(k) clearance and CLIA Waiver by Application. All other content that would otherwise be included in separate, sequential 510(k) and CLIA Waiver by Application submissions should be included in a Dual Submission.

In addition to the information required in a 510(k) provided in 21 CFR 807.87, the following FDA guidances are applicable:

• Format for Traditional and Abbreviated 510(k)s
• Refuse to Accept Policy for 510(k)s
• And, as available, device-specific guidances

Additionally, FDA recommends you include the following in a Dual Submission:

• Device Description and Determination That Device is “Simple” A description of your device that demonstrates it is simple to use.
• Risk Analysis The results of a risk analysis, including the identification of potential sources of error for your device.
• Failure-Alert and Fail-Safe Mechanisms The results of risk evaluation and control, including a description of (1) measures you have implemented to mitigate the risk of errors, and (2) validation and/or verification studies demonstrating the ability of failure alerts, fail-safe mechanisms, and other control measures that you have incorporated into your device to mitigate the risk of errors, even under conditions of stress.  ‍
• Flex Studies The results of flex studies demonstrating insensitivity of the test system to environmental and usage variations under conditions of stress.
• ‍Analytical Studies A description of the design and results of analytical studies of the device conducted at an internal site including, but not limited to, the following: - Analytical sensitivity (Limit of Detection (LoD) or C5-C95 for qualitative tests); - Measuring interval (Limit of Quantitation (LoQ) and Limit of Blank (LoB)/LoD, if applicable, for quantitative tests); - Analytical specificity (interferences, cross-reactivity,etc.); - Linearity (for quantitative tests); - Precision (if needed for lot-to-lot variability and/or other issues); - Carry-over (if applicable); - Reagent stability; and - Sample stability. ‍
• Comparison Study A description of the study design and results of comparison studies you conducted to demonstrate that the device has an insignificant risk of an erroneous result when performed by untrained operators.
• Reproducibility Study A description of the study design and results of reproducibility studies of the device performed by untrained operators.
• Clinical Performance Study Most IVD 510(k) submissions do not include a clinical performance study. However, for some devices, a clinical performance study may be needed for either a 510(k) or Dual Submission (please contact FDA through a Pre-Submission for further discussion). ‍
• Labeling Proposed device labeling, including instructions for use consistent with a device that is “simple.”

Related FAQs:What is the purpose of the medical device tracking regulation, according to CAPA? How do you report corrections or removals for a medical device to the FDA?What happens if there are corrections and removals to a medical device, according to CAPA?What is the purpose of MDR?What is the purpose of CAPA?See More FAQsProxima NewsletterRants, raves and observations. Occasionally an opinion or fact.Thank you! Your submission has been received!Oops! Something went wrong while submitting the form.ExpertiseMedTechBiotechResourcesResource HubInsightsVideo HubCompanyAboutPeopleCareersCompany UpdatesPrivacy PolicyConnect2450 Holcombe Blvd. Houston, TX [email protected]+1.281.306.3127Proxima CRO is headquartered in Houston, Texas© Copyright 2026 Proxima CRO All Rights Reserved.MedTechNo items found.Compliance & Regulatory: MedTechGuidelines & StandardsClinical Trials